GRP logo
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report-Part V

The citation for this report is:
Mycka JM, Dellamano R, Kolassa EM, et al. Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report-Part V. Value Health 2010;13:25-7.

Translations: » 中文

Task Force Leadership Group
Jack M. Mycka, Industry Subgroup Chair & Global President and CEO, MME LLC, Montclair, NJ, USA
Renato Dellamano PhD, President, MME Europe & ValueVector, Milan, Italy
Sabyasachi Ghosh PhD, Research Assistant, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
E.M. “Mick” Kolassa MBA, PhD, MME LLC, Montclair, NJ, USA
Michael Wonder BSc (Hons), BPharm., Director, Global Pricing and Market Access Operations, Novartis Pharma AG, North Ryde, NSW, Australia

For recommendations on how drug costs should be measured for cost-effectiveness analysis from other key analytic perspectives, please refer to the following reports:

FINAL REPORT
The Drug Cost Standards Task Force presented their reports including responses to member comments during an open forum at ISPOR’s 14th Annual International Meeting in Orlando, FL in May 2009. The task force’s forum presentation can be viewed at: Forum Presentation


ISPOR Good Practices For Outcomes Research Index